Welcome to our dedicated page for Biodexa Pharmaceuticals Plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biodexa Pharmaceuticals plc filings document a foreign private issuer that reports current information on Form 6-K and incorporates certain disclosures into Form S-8 and Form F-3 registration statements. The records cover preliminary annual results; pipeline disclosures for eRapa, MTX240 and tolimidone; clinical trial authorizations and enrollment updates; and material agreements such as the MTX240 license and collaboration arrangement.
Capital-structure disclosures describe ADS units, pre-funded warrants, Series L warrants, public-offering documents, ADR ratio matters and the relationship between ADSs and ordinary shares. Governance and corporate filings also cover executive and board appointments, exhibit-based press releases, and other foreign-issuer current reports tied to Biodexa’s biopharmaceutical development programs.
Biodexa Pharmaceuticals PLC updates its prospectus for a previously completed “best efforts” offering by incorporating a new Form 6-K. The registration covers up to 97,800 ADSs representing 4,890,000 ordinary shares underlying pre-funded warrants, up to 1,219,512 ADSs representing 60,975,600 ordinary shares underlying Series L warrants, and up to 30,487 ADSs representing 1,524,350 ordinary shares underlying placement agent warrants, issuable on a continuous basis.
Shareholders approved all resolutions at the July 29, 2026 general meeting, including a one-for-10,000 reverse stock split of ordinary shares, authority to allot up to £25,000,000 for future share issuances through the 2029 AGM, and adoption of new articles of association. Concurrently, the ADS ratio will change by a factor of 10,000 to one ADS per 50 ordinary shares, which is stated not to alter proportional ownership. Biodexa’s ADSs trade on Nasdaq under “BDRX,” with a last reported closing price of $1.42 on August 3, 2026.
Biodexa Pharmaceuticals PLC is updating a resale registration covering up to 10,950 ordinary shares, represented by 219 American Depositary Shares (ADS), by incorporating new information from a July 2026 Form 6-K.
Shareholders approved a one-for-10,000 reverse stock split of the company’s ordinary shares, expected to be effective as of July 30, 2026, along with authority to allot up to £25,000,000 of shares for future issuances through the 2029 annual general meeting and the adoption of new Articles of Association. Concurrent with the reverse split, the ADS ratio will change from 1 ADS per 500,000 ordinary shares to 1 ADS per 50 ordinary shares, which the company states will not itself constitute a reverse split of the ADSs or alter proportional ownership of ordinary or ADS holders. The company’s ADSs trade on Nasdaq under the symbol BDRX, with a last reported closing price of $1.42 on August 3, 2026.
Biodexa Pharmaceuticals PLC filed a prospectus supplement for the resale by existing selling shareholders of up to 17,150 ordinary shares, represented by 343 American Depositary Shares (ADS). The ADSs trade on NASDAQ under the symbol BDRX, with a last reported closing price of $1.42 on August 3, 2026.
The company reports that shareholders approved a one-for-10,000 reverse stock split of the ordinary shares and an authority to allot up to £25,000,000 of share capital for future issuances through the 2029 annual general meeting. Concurrently with the reverse split, the ADS ratio will change from 1 ADS per 500,000 ordinary shares to 1 ADS per 50 ordinary shares; this change is stated not to constitute a reverse split of the ADSs and not to alter proportional ownership for holders of ordinary shares or ADSs.
Biodexa Pharmaceuticals PLC is registering the resale by a selling shareholder of up to 127,754,750 Ordinary Shares represented by 2,555,095 American Depositary Shares (each ADS equals 50 Ordinary Shares), all issuable upon exercise of pre-funded and Series M, N and O warrants. The company will not receive proceeds from these resales but will receive cash only upon warrant exercises. Ordinary Shares outstanding were 51,453,281 before this registration and would be 179,208,031 if all warrants are exercised.
Biodexa is a clinical-stage biopharmaceutical company developing eRapa for FAP and NMIBC, MTX240 for GIST, and tolimidone for type 1 diabetes, while de‑prioritizing MTX110 and legacy delivery platforms. Recent financings include a July 2026 registered direct offering (~$0.8 million), a private placement (~$1.0 million) and a warrant inducement (~$1.7 million). A one‑for‑10,000 reverse split and multiple ADS ratio changes were completed to maintain NASDAQ listing. As of December 31, 2025, cash was £8,534k (pro forma £10,630k) and total equity was £11,405k (pro forma £13,501k).
Biodexa Pharmaceuticals PLC has filed a pre-effective amendment to register the resale of up to 127,754,750 Ordinary Shares, represented by 2,555,095 American Depositary Shares (ADSs), issuable upon exercise of pre-funded and Series M, N and O warrants held by a single selling shareholder. This is a resale registration; all sale proceeds from ADS resales will go to the selling shareholder, while Biodexa would receive cash only if the warrants are exercised for cash at their stated exercise prices.
The company reports 51,453,281 Ordinary Shares outstanding before warrant exercise and up to 179,208,031 Ordinary Shares assuming all warrants are fully exercised, indicating substantial potential dilution. Biodexa remains a clinical-stage biopharmaceutical company focused on eRapa for FAP and NMIBC, MTX240 for GIST, and tolimidone for type 1 diabetes, with fast track designation for eRapa and a $3.0 million CPRIT grant supporting its Phase 3 FAP program. Recent financing activity includes a July 2026 registered direct offering, a warrant inducement, and a private placement, each issuing warrants now covered by this resale registration.
Biodexa Pharmaceuticals PLC reported that shareholders approved all four resolutions at a General Meeting on July 29, 2026, including a one-for-10,000 reverse stock split of its ordinary shares, which have a nominal value of £0.000001 each. Shareholders also authorized the allotment of up to £25,000,000 for future share issuances through the 2029 annual general meeting and approved new Articles of Association reflecting these changes.
The share capital reorganization, effective from 08.00 BST (03.00 EDT) on July 30, 2026, reduces the number of ordinary shares outstanding by a factor of 10,000. Following the reorganization, 51,453,281 ordinary shares of £0.000001 each will be outstanding, equivalent to 1,029,063 American Depositary Shares (ADSs), the same number of ADSs as before. Concurrently, the ratio of ordinary shares per ADS will change from 500,000:1 to 50:1. The company states that these adjustments do not change the proportional ownership of holders of ordinary shares or ADSs, other than potential effects from the treatment of fractional entitlements.
Biodexa Pharmaceuticals PLC is registering for resale up to 1,277,547,500,000 Ordinary Shares represented by 2,555,095 American Depositary Shares, all issuable upon exercise of pre-funded, Series M, Series N and Series O warrants held by existing investors. All sale proceeds will go to the selling shareholders; Biodexa will receive cash only if these warrants are exercised, primarily at $2.85 per Depositary Share or $0.0001 for pre-funded warrants.
Total Ordinary Shares outstanding could rise from 452,032,808,922 to 1,729,580,308,922 if all warrants are exercised, creating substantial potential dilution and overhang. Biodexa is a clinical-stage biopharmaceutical company advancing eRapa (fast track designation, Phase 3 in FAP and Phase 2 in NMIBC), MTX240 for GIST and tolimidone for type 1 diabetes, while de-prioritizing MTX110 and closing its Cardiff laboratory. Recent July 1, 2026 financings, including a registered direct offering, a warrant inducement and a private placement, generated aggregate gross proceeds of approximately $0.8 million, $1.7 million and $1.0 million, respectively. Audit reports on recent financial statements contain explanatory paragraphs regarding Biodexa’s ability to continue as a going concern.
Biodexa Pharmaceuticals PLC has called a General Meeting for 29 July 2026 to approve a major share capital reorganisation and new share issuance authorities.
The company proposes a 10,000:1 consolidation of its existing ordinary shares, immediately followed by a subdivision into new ordinary shares of £0.000001 and a new class of E deferred shares. The board explains this is intended to rationalise an exceptionally large number of shares while keeping shareholder rights and proportional ownership unchanged, although holders of fewer than 10,000 shares would lose their ordinary shareholding after consolidation.
The company also seeks authority to allot shares or rights over shares up to an aggregate nominal value of £25,000,000.00, and to disapply statutory pre-emption rights on the same nominal amount until the annual general meeting to be held in 2029. Management notes this flexibility is aimed at acquisitions and financings to expand a pipeline focused on rare and orphan products and oncology. A related resolution would adopt new articles of association to reflect the new E deferred shares. The ratio of American Depositary Shares would change so that each ADS represents 50 new ordinary shares, with the total number of ADSs remaining the same.
Biodexa Pharmaceuticals PLC filed a Prospectus Supplement to its Form F-1 and a Form 6-K describing a set of securities transactions. The supplement covers the resale registration of 299,261,500,000 ordinary shares, represented by 598,523 ADSs, and the Company disclosed Offerings consisting of a Registered Direct Offering, concurrent private placements and a warrant inducement to raise proceeds.
The Registered Offering includes the sale of 82,809 ADSs at $2.85 each and 200,143 Registered Pre-Funded Warrants at $2.8499 each (each pre-funded warrant exercisable for one ADS at $0.0001). The Company also agreed to issue multiple series of unregistered warrants (Series M, N and O) contingent on shareholder approval. Aggregate gross proceeds from the Offerings and the Warrant Inducement are stated as approximately $3.54 million. The Prospectus Supplement incorporates a Form 6-K and a press release dated June 30, 2026.